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Introduction
Progressive loss of efﬁcacy after glau-
coma surgery remains an unsolved
problem.
Many adjunctive procedures,
such as the use of antimetabolites,
implants, bleb needling, suture lysis
and amniotic membrane transplanta-
tion (Melamed et al.1990; Kitazawa
et al. 1991; Skuta et al. 1992; Kolker
et al. 1994; Smith et al. 1997; Meyer
et al. 1997; Tezel et al. 1998; Fujishi-
ma et al. 1998; Membrey et al. 2000;
Singh et al. 2000; Yue et al. 2003;
Feyi-Waboso & Ejere 2004; Ambresin
et al. 2002; Moreno-Lopez & Perez-
Alvarez 2006), have been proposed to
enhance and maintain the hypotensive
effect of trabeculectomy or deep scler-
ectomy. Evidence-based data indicate
that the use of mytomicin-C (MMC)
during trabeculectomy has a signiﬁ-
cant positive effect on postoperative
intraocular pressure (IOP) (Jampel
et al. 2002; Wilkins et al. 2005). In
our experience, MMC can be regarded
as an enhancement of the deep scler-
ectomy IOP-lowering effect without
evidence of antimetabolite-related
complications (Cillino et al. 2005). On
the other hand, MMC-augmented
glaucoma surgery can be associated
with a signiﬁcantly higher frequency
of late bleb leaks (Anand & Atherley
2005; Anand et al. 2006).
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ABSTRACT.
Purpose: To test the expanded polytetraﬂuoroethylene (ePTFE) as a new adju-
vant in trabeculectomy.
Methods: Consecutive glaucoma surgical inpatients were observed at the
Department of Ophthalmology of Palermo University. Sixty patients (60 eyes)
were randomly assigned to undergo trabeculectomy (T), trabeculectomy with
mitomycin-C (TMMC), with ePTFE (TG) or with mitomycin-C and ePTFE
(TGMMC). Postoperative visits were scheduled at 24 hr, 7 days, 1, 3, 6, 12,
18 and 24 months. Complete success and qualiﬁed success were assessed
at two target intraocular pressure (IOP) levels – £21 and £17 mmHg – by
Kaplan–Meier curves.
Results: The postoperative IOP reduction was signiﬁcant (P < 0.01) at the
endpoint in all groups, with a mean IOP of 16.9 (±2.9), 16.2 (±2.7), 15.3
(±3.4) and 15.2 (±4.3) mmHg in T, TMMC, TG and TGMMC eyes,
respectively. No intergroup difference was found at either IOP targets. The
Kaplan–Meier curves relating to either the £21 mmHg or the £17 mmHg tar-
get IOP did not show signiﬁcant intergroup differences for complete and quali-
ﬁed success rate. When ePTFE was used, a trend favouring the medium-term
survival rate was noted. No adverse reaction to the ePTFE was present, and
no membrane extrusion or conjuctival erosion were noted in any cases. Hypo-
tony was signiﬁcantly more frequent (P = 0.035) in groups without ePTFE.
Moreover, the late MMC-related complications were more frequent when
MMC was applied.
Conclusion: Expanded polytetraﬂuoroethylene implant in trabeculectomy is well
tolerated and could act as a ﬁltration modulating device. Therefore, it is useful
in reducing early hypotony-related complications and contributes to attaining
medium-term IOP control that is comparable to the low-dosage MMC.
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A detailed database search (Medline
and PubMed) failed to show any
report on the use of synthetic implant
materials as adjuvants in penetrating
glaucoma surgery (Jampel et al. 2002;
Wilkins et al. 2005).
Since 1978, expanded polytetraﬂu-
oroethylene (ePTFE: Gore-Tex or
Zytex) has been widely used in car-
diac and gynaecological surgery and
soft-tissue augmentation with minimal
complications, being regarded as one
of the most chemically inert and bio-
compatible materials known (Sakam-
oto et al. 1978; Meus et al. 1983;
Monk et al. 1998; Giovanni et al.
1999). Expanded polytetraﬂuoroethyl-
ene is made up of a number of solid
nodes inter-connected by a matrix of
thin ﬁbrils. The peculiarity of this
non-reabsorbable material is micropo-
rosity, watertightness at low pressure,
gas and water vapour permeability
and the ability to minimize tissue
attachment to the material in recon-
structive procedures. The usefulness of
ePTFE substitutes in providing a clear
plane of dissection and minimizing
adhesions has also been documented
in both experimental investigations
and clinical studies (Sterling 2002;
Kawaguchi et al. 2003).
In particular, the PRECLUDE
pericardial ePTFE membrane, a peri-
cardial substitute, allows control of
adhesions between tissues and artiﬁ-
cial surfaces by modulation of the size
of interstices. The membrane thickness
is 0.1 mm with a pore size of <1 lm.
This small pore size excludes tissue
ingrowth, limiting attachment between
the membrane and adjacent structures.
The explanted PRECLUDE ePTFE
membranes that were examined histo-
logically showed loosely adherent cells
at the tissue–membrane interface and
no evidence of collagen or cellular
inﬁltration. PRECLUDE pericardial
membrane is a white, opaque mate-
rial, but after implantation the mate-
rial becomes wet with proteinaceous,
aqueous ﬂuids and turns translucent.
This is because of its microporous
nature and the thinness of the mate-
rial; this usually occurs within 2–6
weeks (Minale et al. 1988; Leprince
et al. 2001).
Expanded polytetraﬂuoroethylene
has also been used in the ophthalmo-
logical ﬁeld in experimental reports,
as a substitute of silicone sponge
in scleral buckling procedure, as a
reinforcement material over the tubes
of glaucoma drainage implants or as
an artiﬁcial meshwork wick in rabbit
eyes (Tawakol et al. 1989; Helies et al.
1998; Jacob et al. 2001). Moreover,
Gore-Tex patches have been clini-
cally used in Mooren’s ulcer, necrotiz-
ing scleritis and rheumatic corneal
ulcer (Huang et al. 1994; Amm &
Nolle 2002).
Recently, a tube implant made of
ePTFE membrane (Gore-Tex) has
been successfully used to treat refrac-
tory glaucoma patients on a long-term
basis (Kim et al. 2003).
In this paper, we report our experi-
ence in the use of a thin membrane
of expanded polytetraﬂuoroethylene
(PRECLUDE pericardial ePTFE
membrane) as a new adjuvant in tra-
beculectomy.
In particular, we carried out a ran-
domized clinical trial with the aim of
verifying the safety and efﬁcacy of an
ePTFE membrane patch as an adju-
vant in trabeculectomy (alone or
combined with low-dosage MMC)
compared to simple trabeculectomy
(with or without low-dosage MMC)
in maintaining the ﬁstula in penetrat-
ing glaucoma surgery.
We tested the possibility that the
ePTFE membrane, placed beneath the
scleral ﬂap, could allow a better and
longer lasting IOP reduction. This
effect could derive from a reduction
of the cicatricial sealing area between
the scleral ﬂap and the scleral bed
because of the ability of the inter-
posed ePTFE membrane to minimize
tissue attachment, as mentioned ear-
lier. Moreover, the interposed mem-
brane could act as a modulating
barrier against excessive ﬁltration in
the early and ⁄or late postoperative
period. Practically, we veriﬁed
whether the Preclude ePTFE mem-
brane, especially in association with
MMC, could represent a viable tool




This study was a randomized, parallel
four-group clinical trial.
Randomization was determined just
before surgery. Sixty patients – 15 for
each surgical technique – were ran-
domly assigned based on a surgical
chart number to undergo a trabeculec-
tomy (T) (which served as surgical
control group), a trabeculectomy with
mitomycin-C (TMMC), a trabeculec-
tomy with GORE PRECLUDE
pericardial implant (TG) or a trabecu-




Consecutive Caucasian glaucoma sur-
gical patients observed at the Depart-
ment of Ophthalmology of the
University of Palermo between 1 Sep-
tember 2003 and 31 August 2004 were
selected. Ethical committee approval
for ePTFE clinical use was obtained
(No. 8 ⁄ 03). Sixty patients (60 eyes)
were enrolled (considering an alpha
error of 0.05 and beta error of 0.20)
according to the inclusion and exclu-
sion criteria. Inclusion criteria were:
age 18 or older, diagnosis of primary
open-angle glaucoma (POAG) or
pseudoexfoliation glaucoma (PEXG),
inadequate IOP control (IOP
>21 mmHg) and ⁄or progressive
visual ﬁeld deterioration under maxi-
mum tolerated medical therapy. Other
required inclusion criteria were avail-
ability, willingness and sufﬁcient cog-
nitive awareness to comply with
examination procedures. Exclusion
criteria were: concurrent participation
during the last 30 days in any other
clinical trial, use of systemic or ocular
medications that may affect vision,
acute or chronic disease or illness that
would increase the operative risk or
confound the outcomes of the study
(e.g. immunodeﬁciency, connective
tissue disease, diabetes, etc.), uncon-
trolled systemic or ocular disease
other than glaucoma, clinically signiﬁ-
cant cataract where combined surgery
was indicated, history of ocular
trauma or prior ocular surgery.
Patients were thoroughly informed
about the procedures, and written
informed consent was obtained.
Eligible patients were admitted to
hospital and underwent a complete
preoperative ophthalmological exami-
nation the day before surgery to
record the baseline values of study
variables.
The preoperative visit collected the
following data for each patient: age,
gender, medical history including pres-
ence of ocular pathology, number and
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type of antiglaucomatous drugs used,
applanation tonometry performed
24 hr before surgery under maximum
tolerated topical therapy, slit-lamp
examination, visual ﬁeld testing by
Humphrey visual ﬁeld.
Surgical techniques
Patients underwent surgery during the
second day of hospitalization. All
operations were carried out, under
peribulbar anaesthesia, by two sur-
geons (S.C. and L.Z.) who were well
trained and experienced in the proce-
dures. During a previous training
curve, ﬁve glaucomatous volunteers
with uncontrolled IOP greater than
21 mmHg had undergone trabeculec-
tomy with PRECLUDE ePTFE
implant. One case experienced a par-
tial membrane extrusion 1 month
postoperatively, because of unstable
insertion, after which the ePTFE
patch was secured to the scleral bed
by one nylon 10-0 suture in all cases.
The technique included superior
rectus muscle grasping with a 4-0 trac-
tion silk suture in all cases. After
creating a superior fornix-based con-
junctival ⁄ tenonian ﬂap, the sclera was
exposed and lightly cauterized to
avoid any retraction after the scleral
ﬂap was obtained. A 5.0 · 4.0 mm
wide and about 300lm thick scleral
ﬂap was dissected using a precalibrat-
ed round blade (Sharpoint, Surgical
Specialities Corporation, Reading,
PA, USA) or diamond knife (Meyco,
Janache S.n.l., Como, Italy) and a
bevel-up crescent knife (Alcon, Milan,
Italy) at 12 o’clock position. When an
ePTFE membrane implant was sched-
uled, two intrascleral pockets were
dissected with a bevel-up crescent
knife, continuing the scleral bed under
the ﬂap at its two vertical edges, with
an extension of at least 0.5 mm. When
MMC use was scheduled, a ﬂuid-
retaining sponge (such as a Weck-cell
sponge), fashioned to be approxi-
mately 7 · 3 mm in length and width
and about 0.5 mm in depth, was
soaked with MMC in a concentration
of 0.2 mg ⁄ml and placed on the
scleral bed under the scleral ﬂap, as
described in a previous study (Cillino
et al. 2005). The sponge was left in
position for 2 min, with the conjuncti-
val ﬂap pulled over the scleral ﬂap in
order to make the Tenon’s-capsule
side of the conjunctiva get in contact
with the MMC. The sponge was
removed with a forceps and the eye
irrigated with 15 ml of balanced salt
solution. A temporal paracentesis was
performed and the anterior chamber
was irrigated with a 1% acetylcholine
solution (Myochol, Novartis Pharma-
stein AG, Stein, Switzerland). An oph-
thalmic viscoelastic device (Healon,
AMO Inc., Santa Ana, CA, USA;
Ophthalin, Ioltech SAS, La Rochelle
and Carl Zeiss Meditec Le Pecq,
France) was injected at the paracente-
sis site to increase the iris–cornea dis-
tance, and thereafter a block of
corneoscleral wall, with an area of
about 1 mm2, was amputated with a
30 disposable blade and Vannas scis-
sors until a pigmented trabecular line
was observed on the specimen. After
performing iridectomy, a 0.1 mm
thick ePTFE membrane (GORE
PRECLUDE pericardial W.L. Gore
and Associates Inc., Flagstaff, AZ,
USA) was inserted, when scheduled,
over the trabeculectomy area into the
two intrascleral pockets previously
dissected. In particular, a rectangular
6 · 3 mm ePTFE patch was fashioned
by straight Vannas scissors, trimming
the four angles to obtain an octagonal
ﬁgure. This patch was then repeatedly
perforated on its surface with a cor-
neal 1 · 2 teeth microsurgical forceps
creating multiple parallel arrows and
inserted by the short sides into the
pockets (Fig. 1). The patch was
secured to the scleral bed with one
nylon 10-0 suture to avoid early post-
operative dislocation. The holes
should guarantee aqueous ﬁltration,
avoiding early closure of the ﬁstula by
the watertight membrane, and facili-
tate the proliferation of late ﬁbrovas-
cular bridges to anchor this no-stick
patch to the surrounding scleral envi-
ronment.
The scleral ﬂap was closed with two
nylon 10-0 sutures at each corner,
avoiding excessive tension. The con-
junctival ﬂap was sutured with 10-0
nylon sutures. The ﬁltration was
assessed by balanced salt solution
injected via the paracentesis.
Postoperatively, all groups were
treated by topical steroid ⁄ antibiotic
drops four times daily for 15 days, then
two times daily for 15 days. Instillation
of 1% atropine drops was added dur-
ing the ﬁrst few days. Atropine was
continued up to 2 weeks in cases with
hypotonus-related complications.
Main outcome measures
Postoperative visits were scheduled at
24 ± 4 hr, then at 7 ± 1 days, 2 and
3 weeks, 1, 2, 3, 6, 12, 18 and
24 months. Unscheduled visits were
allowed according to the patients’
needs or the examiners’ judgment and
were recorded carefully. Two and
3 week data have not been included in
the statistical analysis. All patients
completed the 24 month follow-up
period.
IOP was the primary outcome mea-
sure. The baseline IOP value was the
IOP measured at the preoperative visit
24 hr before surgery. In case of post-
operative IOP measurements higher
than 21 mmHg after topical steroid
withdrawal, IOP-lowering medication
Fig. 1. Trabeculectomy with expanded polytetraﬂuoroethylene (ePTFE) membrane implant:
perforated ePTFE patch insertion.
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was added. We decided not to per-
form suturelysis or needling in any
case, to avoid bias because of the use
of further adjuvant procedures besides
ePTFE or MMC.
Postoperative IOP level, number of
antiglaucoma medications and early or
late postoperative complications were
checked at each control, to evaluate
indirectly (as stated earlier) the degree
of cicatricial failure and ⁄or excessive
outﬂow in ePTFE-augmented trabecu-
lectomy versus ePTFE plus MMC-
augmented, MMC-augmented or
simple trabeculectomy. Moreover, bleb
avascularity, transconjunctival oozing,
delayed bleb leaks and hypotonus
maculopathy were evaluated as signs
of MMC-related complications.
Complete success was deﬁned as a
normal endpoint IOP without anti-
glaucoma medications, while qualiﬁed
success was deﬁned as a normal end-
point IOP with or without medica-
tions. These categories were assessed
at two target IOP levels – £21 and
£17 mmHg – in all four groups.
Statistical analysis
The sample size was chosen to assure a
power of 90% or more in detecting at
least a 3 mmHg difference among
groups and a standard deviation (SD)
of 3 mmHg, with a two-sided alpha
error of 5% and beta error of 20%.
Randomization was determined just
before surgery by sealed-envelope tech-
nique. Demographic variables and
other baseline variables were tabulated
and checked for homogeneity among
the four treatment groups. Parametric
and non-parametric variables were
compared by univariate analysis of
variance (anova) and Kruskal Wallis
statistic test, respectively, to evaluate
surgical intergroup differences; discrete
variables were analysed using the chi-
square test. The paired Wilcoxon
signed-rank test and the paired sam-
ples Student’s t-test were used for non-
parametric and parametric analysis,
respectively, to evaluate intragroup
differences at different time periods.
The proportion of surgical failures and
adverse events in each treatment group
was compared. All statistical tests were
two-tailed and were applied at the 5%
signiﬁcance level. Success was evalu-
ated on the basis of Kaplan–Meier
cumulative probability (log rank test).
Data were analysed with Epi Info
software, version 3.2.2 (Centers for
Disease Control and Prevention,
Atlanta, Georgia, USA) and the spss
Software (version 14.0; SPSS Inc., Chi-
cago, Illinois, USA).
Results
Patients in the four treatment groups
did not signiﬁcantly differ for age, sex,
type of glaucoma, mean number of
preoperative medications and duration
of the preoperative topical antiglauco-
ma therapy (Table 1). The mean pre-
operative IOP (±SD) was 28.6 (±5.2)
in T eyes, 30.9 (±6.1) in TMMC eyes,
35.3 (±5.1) mmHg in TG eyes and
30.6 (±4.8) in TGMMC eyes, without
signiﬁcant intergroup difference. One
day postoperatively, the IOP dropped
at 8.4 (±2.1), 8.7 (±4.5), 10.6 (±6.7)
and 10.4 (±3.7) mmHg, respectively
(Table 2), without signiﬁcant inter-
group difference but with a signiﬁcant
difference (P < 0.01) relating to the
preoperative value in each group. The
postoperative IOP reduction was still
signiﬁcant at the endpoint in all groups
with respect to the preoperative value
(P < 0.01), with a mean IOP of 16.9
(±2.9), 16.2 (±2.7), 15.3 (±3.4) and
15.2 (±4.3) mmHg in T, TMMC, TG
and TGMMC eyes, respectively
(Table 2). The ﬁrst day and ﬁrst week
IOP was signiﬁcantly lower when com-
pared to the ﬁrst month IOP value in T
and TMMC cases (P < 0.05 and
P < 0.01, respectively) (Table 2).
No intergroup difference was pres-
ent at any scheduled postoperative
observation time (Table 2, Fig. 2).
The mean number of antiglaucoma
medications was signiﬁcantly reduced
(P < 0.001) at the endpoint in all
groups: from 2.6 (±0.2) to 0.7 (±0.2),
from 2.7 (±0.1) to 0.6 (±0.2), from
2.5 (±0.6) to 0.7 (±0.1) and from 2.5
(±0.4) to 0.5 (±0.4) in T, TMMC, TG
and TGMMC, respectively, without
signiﬁcant intergroup differences.
The success rates in the study
groups are reported in Table 3. In
particular, when a £21 mmHg target
IOP without medications (complete
success) was considered, it was
achieved in eight eyes (53.3%) in the
T group, eight eyes (53.3%) in the
TMMC group, 10 eyes (66.7%) in
the TG group and nine eyes (60%) in
the TGMMC group, without signiﬁ-
cant difference. When a £21 mmHg
target IOP with or without medica-
tions (qualiﬁed success) was consid-
ered, 13 (86.7%) eyes in the T group
and 14 (93.3%) eyes in each of the
remaining groups were respectively
found, again without signiﬁcant inter-
group difference. When a £17 mmHg
target IOP without medications (com-
plete success) was considered, ﬁve eyes
(33.3%), seven eyes (46.7%), 10 eyes
(66.7%) and nine eyes (60%) were
found in the T, TMMC, TG and
TGMMC groups, respectively. As for
a £17 mmHg target IOP with or with-
out medications (qualiﬁed success), 11
eyes (73.3%) in the T group, 10 eyes
(66.7%) in the TMMC group and 12
eyes (80%) in both the ePTFE-patch-
augmented (TG and TGMMC)
groups were found, respectively, with-
out statistically signiﬁcant difference.
The Kaplan–Meier cumulative sur-
vival curves relating either the
£21 mmHg target IOP or £17 mmHg
target IOP (Figs 3 and 4) did not
show signiﬁcant intergroup differences
as for complete and qualiﬁed success
Table 1. Characteristics of the glaucoma patients.
T TMMC TG TGMMC P
Eyes 15 15 15 15 –
Male ⁄ female 8 ⁄ 7 9 ⁄ 6 7 ⁄ 8 6 ⁄ 9 0.721*
Age (mean ±SD), years 71.1 (4.1) 68.1 (6.1) 67.2 (9.0) 65.3 (7.6) 0.194
POAG ⁄ PEXG diagnosis 9 ⁄ 6 10 ⁄ 5 10 ⁄ 5 11 ⁄ 4 0.896*
Mean preoperative IOP (±SD),
mmHg
28.6 (5.2) 30.9 (6.1) 35.3 (5.1) 30.6 (4.8) 0.395
Preoperative drugs, mean (±SD) 2.6 (0.2) 2.7 (0.1) 2.5 (0.6) 2.5 (0.4) 0.900
Mean time (months) from the initial
topical therapy to surgery (±SD)
30.3 (15.8) 31.5 (16.2) 33.4 (18.9) 32.3 (16.4) 0.648
T, trabeculectomy; TMMC, trabeculectomy with mitomycin-C; TG, trabeculectomy with ePTFE;
TGMMC, trabeculectomy with mitomycin-C and ePTFE; POAG, primary open-angle glaucoma;





rate (log rank P = 0.235 and log rank
P = 0.814, respectively) even when
ePTFE is used; a trend favouring the
medium-term survival rate can be
noted. This is more evident regarding
the complete success cases.
Over a 2 month period, the white
ePTFE patch, when implanted, could
be observed under the ﬁltration bleb
area (Fig. 5); it then disappeared
because of complete discoloration of
the patch in all cases.
The frequency of postoperative
complications – i.e. hyphaema, ante-
rior chamber inﬂammation with ﬁbr-
inous reaction, early hypotony
(deﬁned as an IOP <8 mmHg or
<10 mmHg with choroidal detach-
ment or shallow anterior chamber),
shallow or ﬂat anterior chamber,
choroidal detachment – is shown in
Table 4. No adverse reaction to the
ePTFE material was present in the
TG and TGMMC groups, and in no
cases were membrane extrusion or
conjuctival erosion noted. No signiﬁ-
cant intergroup difference was found
in terms of hyphaema and inﬂamma-
tion. Hypotony was signiﬁcantly more
frequent (P = 0.035) in groups with-
out the ePTFE patch (i.e. T and
TMMC) compared to the other two
groups. Moreover, Table 4 indicates
the late MMC-related complications:
cystic-avascular blebs are more (but
not signiﬁcantly) frequent when MMC
(with or without ePTFE) is applied.
Discussion
The postoperative behaviour in the
four glaucoma surgery groups is quite
similar. As stated earlier, all groups
were matched with regard to factors





















Preop 1 day 1 week 1 month
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Fig. 2. Intraocular pressure (IOP) variation over time in the four surgical treatment groups.
Table 3. Success rates (%) in the study groups at two target IOP levels.
T TMMC TG TGMMC P*
£21 mmHg
Complete success 8 ⁄ 15 (53.3) 8 ⁄ 15 (53.3) 10 ⁄ 15 (66.7) 9 ⁄ 15 (60.0) 0.860
Qualiﬁed success 13 ⁄ 15 (86.7) 14 ⁄ 15 (93.3) 14 ⁄ 15 (93.3) 14 ⁄ 15 (93.3) 0.884
£17 mmHg
Complete success 5 ⁄ 15 (33.3) 7 ⁄ 15 (46.7) 10 ⁄ 15 (66.7) 9 ⁄ 15 (60.0) 0.268
Qualiﬁed success 11 ⁄ 15 (73.3) 10 ⁄ 15 (66.7) 12 ⁄ 15 (80.0) 12 ⁄ 15 (80.0) 0.807
T, trabeculectomy; TMMC, trabeculectomy with mitomycin-C; TG, trabeculectomy with ePT-
FE; TGMMC, trabeculectomy with mitomycin-C and ePTFE.
*Pearson’s chi-square test.
Table 2. Pre- and postoperative IOP in the surgical groups.
T TMMC TG TGMMC
PIOP P* IOP P* IOP P* IOP P*
Preoperative
Postoperative
28.6 (5.2) – 30.9 (6.1) – 35.3 (5.1) – 30.6 (4.8) – 0.395
1st day 8.4 (2.1) <0.01 8.7 (4.5) <0.01 10.6 (6.7) <0.01 10.4 (3.7) <0.01 0.486




12.2 (3.8) <0.01 12.0 (3.7) <0.01 0.331
1st month 14.7 (3.7) <0.01§– 15.1 (3.5) <0.01§– 12.4 (2.6) <0.01 14.1 (3.3) <0.01 0.206
3rd month 15.2 (3.8) <0.01 15.3 (3.3) <0.01 16.7 (3.0) <0.01 15.4 (2.4) <0.01 0.854
6th month 16.4 (3.2) <0.01 14.8 (3.0) <0.01 15.8 (4.0) <0.01 16.5 (2.6) <0.01 0.428
9th month 16.1 (2.8) <0.01 15.1 (2.3) <0.01 15.6 (2.9) <0.01 15.8 (2.4) <0.01 0.549
12th month 17.4 (2.7) <0.01 16.4 (2.4) <0.01 16.1 (3.2) <0.01 16.5 (2.3) <0.01 0.610
18th month 16.6 (2.5) <0.01 16.6 (2.5) <0.01 14.8 (3.5) <0.01 15.4 (4.4) <0.01 0.584
24th month 16.9 (2.9) <0.01 16.2 (2.7) <0.01 15.3 (3.4) <0.01 15.2 (4.3) <0.01 0.576
T, trabeculectomy; TMMC, trabeculectomy with mitomycin-C; TG, trabeculectomy with ePTFE; TGMMC, trabeculectomy with mitomycin-C
and ePTFE; IOP, intraocular pressure.
Values for IOP are expressed as mean (±SD).







such as race, age, type of glaucoma,
duration of topical treatment, absence
of any previous ocular surgery, etc.
The endpoint degree of IOP lowering
in the T group does not signiﬁcantly
differ from that found in the groups
where the adjuvants (MMC, ePTFE
or both) were used. As stated in the
Materials and Methods section, we
chose not to perform other adjunctive
procedures such as adjustable ⁄ releas-
able sutures or needling to avoid bias
and because of some contradictory
data. In fact, even if some authors
report favourable outcomes, other
data seem to indicate that releasable
sutures cannot exclude the risk of
hypotony during the ﬁrst postopera-
tive days; they do not seem of great
utility in phakic eyes when used after
10 postoperative days (Stalmans et al.
2006; Kapetansky 2003; Ralli et al.
2006; Fontana et al. 2006). Needling
does not seem signiﬁcantly better than
medical therapy after trabeculectomy
(Feyi-Waboso & Ejere 2004).
During the 2 year follow-up, the
mean IOP was below target values in
all four groups. Indeed, no intergroup
difference is present at any follow-up
time. This ﬁnding is in contrast with
the evidence-based data of a positive
adjuvant effect of intraoperative
MMC in trabeculectomy (Jampel
et al. 2002; Wilkins et al. 2005).
On the other hand, reports indicat-
ing no statistically signiﬁcant differ-
ence in the overall outcome of phaco-
trabeculectomy between control and
MMC groups of non-selected patients
with POAG, or no signiﬁcant dif-
ference in the cumulative success
probability of MMC-augmented tra-
beculectomy compared to trabeculec-
tomy alone, are not infrequent (Shin
et al. 1996; Tsai et al. 2003).
Moreover, the large (5.0 · 4.0 mm)
300lm thick scleral ﬂap we established
to provide protection against excessive
outﬂow reduces the direct contact area
between the underlying MMC sponge
and the overlying conjunctiva, proba-
bly decreasing the antiﬁbrotic effect.
Also, the relatively small sample size
could enhance the lack of homogene-
ity with respect to the postoperative
parameters in our groups.
The postoperative IOP behaviour
from the ﬁrst day to the ﬁrst month
appears to be more stable in the groups
where ePTFE was used i.e. (TG and
TGMMC) than in the T and TMMC
groups, as indicated by the lack of sig-
niﬁcant difference between the ﬁrst
day, ﬁrst week and the ﬁrst month IOP
levels in the two former groups. This
ﬁnding could indicate a sort of modula-
tion of the aqueous outﬂow provided
by the ePTFE barrier, through its small
holes and along its surface, as postu-
lated in the Introduction. This barrier
effect could be of beneﬁt, because a
heavy early IOP reduction is correlated
with more hypotony-related complica-
tions, and has been shown to be very
poorly correlated to 1 year IOP control
in antimetabolite-augmented trabecu-
lectomy (Polikoff et al. 2005).
Even when comparing the TG and
TGMMC groups, no difference in
IOP behaviour because of the adding
of MMC to the ePTFE patch can be
demonstrated in our sample.
We believe that the similar degree
of early hypotony in both the T and
TMMC groups is related to the proce-
dure (i.e. ﬂaps fashioning, suturing
technique, etc.) because the antimetab-
olite effect is not signiﬁcant in the
early postoperative period.
Fig. 3. Kaplan–Meier cumulative probability curve of complete success (without medication)
for intraocular pressure (IOP) <18 mmHg.
Fig. 4. Kaplan–Meier cumulative probability curve of qualiﬁed success (with or without medi-
cation) for intraocular pressure (IOP) <18 mmHg.
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When the complete and qualiﬁed
endpoint success rates are considered,
signiﬁcant intergroup difference is
lacking both at £21 and £17 mmHg
target IOP. In particular, the groups
behave quite similarly at the
£21 mmHg IOP target and rates are
comparable with those of other med-
ium-to-long-term studies (Kitazawa
et al. 1991; Skuta et al. 1992; Smith
et al. 1997; Wilkins et al. 2005;
Anand et al. 2006). However, at the
£17 mmHg target IOP the success
rates – especially the complete ones –
increase from the simple trabeculecto-
my eyes through the MMC-aug-
mented eyes to the ePTFE with or
without MMC eyes, even if the dif-
ferences are still not signiﬁcant. This
trend is clearly shown by the survival
curves and could indicate, if statisti-
cally conﬁrmed by a larger series, a
complementary or additive mechani-
cal non-stick effect of the ePTFE
patch on the antiﬁbrotic MMC
action.
The ePTFE membrane tolerance
was optimal. Eyes in the TG and
TGMMC groups showed no adverse
reaction to the material; neither
inﬂammation nor extrusion nor con-
juctival erosion were noted. Progres-
sive discolouration with disappearance
of the membrane, as already reported
in cardiosurgical practice, was present
in all cases (Minale et al. 1988).
Early hypotony was the only post-
operative complication signiﬁcantly
more frequent in non-ePTFE groups.
This ﬁnding is in agreement with the
instability of IOP during the ﬁrst
month in trabeculectomy cases where
the patch was not inserted (as men-
tioned earlier). The degree and
incidence of late MMC-related com-
plications are not severe with the tech-
nique we performed, irrespective of
the use of ePTFE. However, a limit of
this study could be that the sample
size, which was designed for the
assessment of equivalence in IOP
reduction, may be too small to
properly assess all safety issues. On
the other hand, we chose not to
increase the number of participants
because of the unknown clinical
medium-term ePTFE effects on the
trabeculectomy site.
In conclusion, our results suggest
that ePTFE implant in trabeculectomy
for POAG or PEXG is well tolerated
and could act as a ﬁltration-modulat-
ing device; therefore, it is useful in
reducing early hypotony-related com-
plications, and contributes to attain-
ing a medium-term IOP control
comparable to that achieved through
the use of low-dosage MMC. The
adjunct of other adjuvant procedures
we do not perform in our study, such
as releasable sutures, could enhance
these results. Even if our study indi-
cates that the ePTFE implant is a via-
ble alternative to low-dosage MMC in
terms of medium-term IOP control,
this does not seem enough to allow a
routine switching from MMC to ePT-
FE adjuvant. At the moment, ePTFE
use can be taken into account when
the antimetabolite-related risk is to be
avoided. Moreover, the question of
whether ePTFE plus MMC-aug-
mented trabeculectomy implies a bet-
ter medium-term IOP reduction than
MMC or ePTFE alone is unanswered:
larger randomized clinical trials and
longer follow-up are required to inves-
tigate these issues.
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